GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » Total Inventories

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Total Inventories : $11.93 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals Total Inventories?

Avadel Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was $11.93 Mil. Avadel Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $11.15 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Avadel Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.23.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Avadel Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was 668.73.

Inventory Turnover measures how fast the company turns over its inventory within a year. Avadel Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.14.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Avadel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.41.


Avadel Pharmaceuticals Total Inventories Historical Data

The historical data trend for Avadel Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Total Inventories Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 - - - 10.38

Avadel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.44 5.29 10.38 11.93

Avadel Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Avadel Pharmaceuticals  (NAS:AVDL) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Avadel Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(88.789+0.75 * 22.692+0.5 * 11.928-89.515
-0-0)/96.0969
=0.23

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Avadel Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=11.154/1.522*365 / 4
=668.73

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Avadel Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=1.522 / 11.154
=0.14

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Avadel Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=11.154 / 27.178
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Avadel Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Executives
Thomas S Mchugh officer: Chief Financial Officer 2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass director 4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim officer: Chief Commercial Officer 16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk director 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton director TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson officer: Chief Medical Officer AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn officer: Sr. VP, Technical Operations 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow officer: Chief Medical Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15